07:00 , Sep 12, 2016 |  BC Week In Review  |  Clinical News

Asenapine maleate transdermal patch: Phase III started

Hisamitsu’s Noven Pharmaceuticals Inc. subsidiary began a double-blind, placebo-controlled, international Phase III trial to evaluate 2 dose levels of asenapine maleate transdermal patches in about 612 patients. Hisamitsu Pharmaceutical Co. Inc. (Tokyo:4530), Tosu, Japan  ...
08:00 , Feb 23, 2015 |  BC Week In Review  |  Company News

Hisamitsu Pharmaceutical Co. Inc sales and marketing update

Hisamitsu’s Noven Pharmaceuticals Inc. subsidiary launched 0.025 mg/day Minivelle estradiol transdermal system in the U.S. to prevent postmenopausal osteoporosis. Minivelle now comes in 0.025, 0.0375, 0.05, 0.075 and 0.1 mg/day. The wholesale acquisition cost (WAC)...
07:00 , Oct 13, 2014 |  BC Week In Review  |  Clinical News

Minivelle regulatory update

FDA approved an sNDA from Hisamitsu's Noven Pharmaceuticals Inc. subsidiary for Minivelle estradiol transdermal patch to prevent postmenopausal osteoporosis and for a new low dose. Minivelle is approved to treat moderate to severe vasomotor symptoms...
07:00 , Sep 8, 2014 |  BC Week In Review  |  Company News

Noven, Novartis deal

Hisamitsu Pharmaceutical Co. Inc. (Tokyo:4530, Tosu, Japan)and Novartis dissolved Vivelle Ventures LLC, a JV formed in 1998 between Novartis and Hisamitsu's Noven Pharmaceuticals Inc. subsidiary. Novartis said the partners mutually decided to dissolve the JV,...
07:00 , Jul 21, 2014 |  BC Week In Review  |  Company News

Hisamitsu, ANI Pharmaceuticals deal

ANI acquired from Hisamitsu’s Noven Therapeutics LLC subsidiary the NDA for Lithobid , an extended-release formulation of lithium carbonate for bipolar disorder, for an upfront cash payment of $11 million. Noven will also be eligible...
07:00 , May 26, 2014 |  BC Week In Review  |  Company News

Hisamitsu neurology, inflammation, endocrine/metabolic news

Hisamitsu announced a five-year plan to achieve annual sales of ¥190 billion ($1.9 billion) in its FY18 ending February 2019. The target would be a 26% increase over sales of ¥150.6 billion ($1.5 billion) for...
07:00 , May 5, 2014 |  BC Week In Review  |  Clinical News

HP-3070: Phase I started

Hisamitsu's Noven Pharmaceuticals Inc. subsidiary began a U.S. Phase I trial to evaluate HP-3070 in patients with schizophrenia. Hisamitsu plans to start a U.S. Phase II trial of the product in its fiscal year ending...
07:00 , Apr 28, 2014 |  BC Week In Review  |  Company News

Endo, Hisamitsu, Teikoku Seiyaku, TWi Pharmaceuticals neurology news

Hisamitsu's Noven Pharmaceuticals Inc. subsidiary and TWi reached separate settlements with Endo and Teikoku on patent litigation related to Endo's Lidoderm lidocaine topical patch. Endo and Teikoku filed suit in the U.S. District Court for...
07:00 , Mar 31, 2014 |  BC Week In Review  |  Company News

Actavis, Hisamitsu neurology news

Hisamitsu's Noven Pharmaceuticals Inc. subsidiary granted Actavis a non-exclusive, royalty-bearing license to market a generic version of Daytrana methylphenidate transdermal system for ADHD beginning on Sept. 1, 2015. The deal settles all outstanding patent litigation...
08:00 , Jan 27, 2014 |  BC Week In Review  |  Company News

Hisamitsu, Shionogi sales and marketing update

Hisamitsu's Noven Pharmaceuticals Inc. subsidiary and Shionogi will exclusively co-promote Brisdelle paroxetine in the U.S. The low-dose selective serotonin reuptake inhibitor (SSRI) is approved to treat moderate to severe vasomotor symptoms (VMS) - hot flashes...